[
  {
    "criterion": "Provides overly technical information on CGRP antagonists",
    "axis": "communication_quality",
    "point": -4
  },
  {
    "criterion": "Accurately compares the side effect profiles of erenumab, galcanezumab, and older prophylactics",
    "axis": "accuracy",
    "point": 7
  },
  {
    "criterion": "Fails to provide any information on the approximate cost of CGRP antagonists",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "Incorrectly states that erenumab and galcanezumab are approved for treating cluster headaches",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Asks the user to clarify the meaning of 'poorly controlled' to better understand their migraine management",
    "axis": "context_awareness",
    "point": 4
  },
  {
    "criterion": "Provides a list of potential new studies on CGRP antagonists, including relevant trial IDs and publication dates",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Uses natural language and correct interpretation in the response",
    "axis": "communication_quality",
    "point": 6
  },
  {
    "criterion": "Does not provide any information on the potential long-term effects of using CGRP antagonists",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Correctly states that erenumab and galcanezumab are not approved for treating cluster headaches",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Provides a clear and concise summary of the current understanding of CGRP antagonists for migraine prevention",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not address the user's question about the cost of CGRP antagonists",
    "axis": "instruction_following",
    "point": -2
  },
  {
    "criterion": "Accurately explains the mechanism of action of erenumab and galcanezumab",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Fails to provide any information on the recommended dosages of erenumab and galcanezumab",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Provides a list of relevant references for the user to consult",
    "axis": "completeness",
    "point": 7
  },
  {
    "criterion": "Incorrectly states that erenumab and galcanezumab are approved for treating chronic migraines",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Correctly states that erenumab and galcanezumab are not approved for treating chronic migraines",
    "axis": "accuracy",
    "point": 9
  }
]